Literature DB >> 20683405

Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer.

Valentin Kolev1, Svetlana Mironov, Oleg Mironov, Nicole Ishill, Chaya S Moskowitz, Ginger J Gardner, Douglas A Levine, Hedvig Hricak, Richard R Barakat, Dennis S Chi.   

Abstract

INTRODUCTION: It has been hypothesized that the supradiaphragmatic lymph nodes serve as the principal nodes for lymphatic drainage of the entire peritoneal cavity. The purpose of this study was to determine the prognostic significance of enlarged supradiaphragmatic nodes noted on preoperative computed tomographic (CT) scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer (EOC).
METHODS: We performed a retrospective chart review of all patients with stage III and IV EOC according to the International Federation of Gynecology and Obstetrics who had preoperative CT scans, including the supradiaphragmatic region, and had undergone primary cytoreductive surgery at our institution between January 1997 and June 2004. Scans were retrospectively reviewed by a radiologist. We defined supradiaphragmatic adenopathy as nodes measuring greater than 5 mm on the largest of 2 perpendicular measurements on the CT scan. The Fisher exact test was used to compare proportions. Kaplan-Meier curves and log-rank tests were used for the survival analyses.
RESULTS: A total of 212 evaluable patients were identified. All underwent attempted primary cytoreduction followed by systemic chemotherapy. None had any supradiaphragmatic nodes removed at primary cytoreduction. With a median follow-up time of 52 months, median overall survival for the entire cohort was 48 months. Of 212 patients, 92 (43%) had supradiaphragmatic adenopathy. Median survival was 50 months for patients without adenopathy and 45 months for patients with adenopathy (P = 0.09). Of the 212 patients, 155 (73%) underwent optimal cytoreduction. In these patients, median survival was 55 months for the 91 without adenopathy and 50 months for the 64 patients with supradiaphragmatic adenopathy (P = 0.09).
CONCLUSIONS: We observed a trend toward worse survival in patients with enlarged supradiaphragmatic nodes. The prognostic impact of supradiaphragmatic adenopathy remains uncertain and deserves further study.

Entities:  

Mesh:

Year:  2010        PMID: 20683405     DOI: 10.1111/IGC.0b013e3181e833f5

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study.

Authors:  Katrijn L M Michielsen; Ignace Vergote; Raphaëla Dresen; Katya Op de Beeck; Ragna Vanslembrouck; Frédéric Amant; Karin Leunen; Philippe Moerman; Steffen Fieuws; Frederik De Keyzer; Vincent Vandecaveye
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

2.  Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer.

Authors:  Anne-Sophie Bats; Florent Hugonnet; Cyrille Huchon; Chérazade Bensaid; Nadia Pierquet-Ghazzar; Marc Faraggi; Fabrice Lécuru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-23       Impact factor: 9.236

3.  PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison.

Authors:  Marcelo A Queiroz; Rahel A Kubik-Huch; Nik Hauser; Bianka Freiwald-Chilla; Gustav von Schulthess; Johannes M Froehlich; Patrick Veit-Haibach
Journal:  Eur Radiol       Date:  2015-05-29       Impact factor: 5.315

Review 4.  Extra-abdominal Lymph Node Metastases as the First Presentation in Ovarian and Fallopian Tube Carcinomas.

Authors:  Maria Lúcia Moleiro; Alfredo Barroco Gouveia
Journal:  Reprod Sci       Date:  2022-08-08       Impact factor: 2.924

5.  Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.

Authors:  Katrijn Michielsen; Ignace Vergote; Katya Op de Beeck; Frederic Amant; Karin Leunen; Philippe Moerman; Christophe Deroose; Geert Souverijns; Steven Dymarkowski; Frederik De Keyzer; Vincent Vandecaveye
Journal:  Eur Radiol       Date:  2013-12-11       Impact factor: 5.315

6.  Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.

Authors:  Renee A Cowan; Jill Tseng; Vijayashree Murthy; Radhika Srivastava; Kara C Long Roche; Oliver Zivanovic; Ginger J Gardner; Dennis S Chi; Bernard J Park; Yukio Sonoda
Journal:  Gynecol Oncol       Date:  2017-09-06       Impact factor: 5.482

7.  Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET/CT in advanced epithelial ovarian cancer.

Authors:  In Ok Lee; Jung-Yun Lee; Hyun Jeong Kim; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Chang Young Lee; Won Jun Kang; Young Tae Kim
Journal:  BMC Cancer       Date:  2018-11-26       Impact factor: 4.430

8.  Gynecologic tumors: how to communicate imaging results to the surgeon.

Authors:  Stefania Rizzo; Giuseppina Calareso; Federica De Maria; Vanna Zanagnolo; Roberta Lazzari; Agnese Cecconi; Massimo Bellomi
Journal:  Cancer Imaging       Date:  2013-12-30       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.